NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a company “Advancing Drugs Through Glycoscience®", today announced it has finalized the statistical analysis of its completed Phase II colorectal cancer trial for 20 previously heavily treated patients, all of whom had at least two previous chemotherapy treatments including; fluorpyrimidines (100%), Irinotecan (100%), Oxaliplatin (100%), and AVASTIN® or ERBITUX® (75%). The study demonstrated the benefit of combining the tumor-targeting polysaccharide, DAVANAT®, to 5-FU for colorectal cancer patients refractory to approved chemotherapies.
